Trasis develops, manufactures and globally distributes radiopharma equipment which synthesises substances that can be used in the diagnosis of various kinds of cancers. This equipment also ensures that medical staff can administer these substances easily and safely. Trasis develops and optimises these synthesis methods to help make the latest developments in radiochemical diagnosis and treatment available to patients more quickly. With 45 employees, Trasis achieved a turnover of over 8.1 million euros in 2016.
Award for young company with strong growth potential
Since 2013, promising young businesses developing strongly in Brussels and Wallonia have been able to compete for the title ‘L’Entreprise Prometteuse de l’Année’. This year, the companies nominated are: Edebex, Lasea, Redpharma and Trasis. Trasis beat the other three companies to succeed Real Impact Analytics, the 2016 winner.
“The jury was particularly impressed with Trasis that systematically manages to make a profit and grow strongly. The company has invested continuously for several years in the niche radiopharma market which is worth billions of euros and in a short timespan has managed to become a true reference in the centres of European nuclear medicine. The ambition and leadership qualities of the two ‘project partners’ convinced us that they make an outstanding team. And that’s how they managed to develop Trasis into ‘L’Entreprise Prometteuse de l’Année’”, highlighted Baron Pierre Rion, President of the jury.
“Since launching the award in 2013, we’ve seen a constant stream of young companies from Brussels and Wallonia with plenty of growth potential and constant enthusiasm. In a short timepan, Trasis has managed to become a true reference in the centres of European nuclear medicine. This is only possible with strong leadership and expertise. The company from Ans is a worthy successor to Real Impact Analysis, the previous year’s winner”, explains Carl Laschet, executive director at EY.